Latest News & Updates

FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer
July 27, 2021

Continue Reading »

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma
July 23, 2021

Continue Reading »

FDA approves belumosudil for chronic graft-versus-host disease
July 16, 2021

Continue Reading »

FDA Approves Enfortumab Vedotin For Locally Advanced/Metastatic Urothelial Carcinoma
July 12, 2021

Continue Reading »

FDA approves pembrolizumab for high-risk early-stage triple-negative breast cancer
July 27, 2021

Continue Reading »

FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma
July 23, 2021

Continue Reading »

FDA approves belumosudil for chronic graft-versus-host disease
July 16, 2021

Continue Reading »

FDA Approves Enfortumab Vedotin For Locally Advanced/Metastatic Urothelial Carcinoma
July 12, 2021

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: